August 8, 2018 / 9:02 PM / 7 months ago

Fed. Circuit upholds decision canceling claims in Durezol eyedrops patent

A federal appeals court on Wednesday upheld a ruling that invalidated a patent covering Novartis AG’s Durezol, opening the door for Akorn Inc to launch a generic version of the eye medication.

The U.S. Court of Appeals for the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board that most claims in the patent, exclusively licensed to Novartis by co-owners Senju Pharmaceutical Co Ltd and Mitsubishi Chemical Holdings Corporation, were invalid as obvious.

To read the full story on WestlawNext Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below